QSI QUANTUM-SI INC

Quantum-Si to Participate at Two Upcoming Investor Conferences

Jul. 29, 2022 -- (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a life sciences company commercializing the first next generation single molecule protein sequencing platform, today announced that it will be participating in two upcoming investor conferences. Patrick Schneider, Quantum-Si’s President and Chief Operating Officer, will participate in fireside chats at both events. The discussions will cover recent company developments, including progress toward commercialization of Quantum-Si’s groundbreaking PlatinumTM instrument, which will be the first system to enable next-generation, single-molecule protein sequencing.

  • Canaccord Genuity 42nd Annual Growth Conference

    Patrick Schneider, President and Chief Operating Officer, will participate in a fireside chat on Wednesday, August 10, 2022 at 8:30 am ET.
  • UBS Genomics 2.0 and MedTech Innovations Summit

    Patrick Schneider, President and Chief Operating Officer, will participate in a fireside chat on Thursday, August 11, 2022 at 3:00 pm PT.

Live and archived webcasts of the events will be available in the Investors section of the Quantum-Si website under .

About Quantum-Si Incorporated

Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at .

EN
29/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on QUANTUM-SI INC

 PRESS RELEASE

Quantum-Si Highlights Major Technical Advances, Next-Generation Platfo...

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced the highlights of an Investor & Analyst event that was hosted in New York City on November 20th, 2024. Quantum-Si’s Management team announced Platinum™ Pro, the Company’s evolution of Platinum, as well as Proteus™, the Company’s new cutting-edge proteomics platform of the future, that is now under development. “We are very excited to have this opportunity to unveil the rapid innovation that we have achieved at Quantum-Si over the ...

 PRESS RELEASE

Avantor to Distribute Quantum-Si’s Next-Generation Protein Sequencing™...

BRANFORD, Conn.--(BUSINESS WIRE)-- (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, has announced a distribution agreement with Avantor® (NYSE: AVTR), a global leader in mission-critical products and services for the life sciences and advanced technology industries. Through this collaboration, Avantor will distribute Quantum-Si's Next-Generation Protein Sequencing (NGPS) portfolio, providing researchers across all market segments in the U.S. and Canada streamlined access to these innovative proteomics solutions. The distribution agreement enables Avanto...

 PRESS RELEASE

Quantum-Si to Develop Acceleration Platform and Advance Core Technolog...

BRANFORD, Conn.--(BUSINESS WIRE)-- (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance Quantum-Si’s core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing. This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus. By leveraging NVIDIA accelerated computing and Quantum-Si’s advanced single-molecule protein sequencing and detection technologies,...

 PRESS RELEASE

Quantum-Si Expands Collaboration with SkyWater to Develop New Chip Pro...

BRANFORD, Conn. & BLOOMINGTON, Minn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™ and (NASDAQ: SKYT), the trusted technology realization partner, announced today they will jointly expand their relationship to support development of Proteus™, Quantum-Si’s next-generation platform designed to transform proteomic research. The expanded collaboration will develop the consumable for Proteus that will enable simultaneous large factor, protein sequencing with unparalleled accuracy. Quantum-Si and SkyWater began par...

 PRESS RELEASE

Quantum-Si and Planet Innovation to Partner on Proteus™

BRANFORD, Conn.--(BUSINESS WIRE)-- (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and Planet Innovation today announced that they will partner on the development and manufacturing of Quantum-Si’s novel proteomics platform, Proteus™. Planet Innovation has a team of over four hundred people with expertise across design, development and manufacturing of scientific instrumentation and medical devices. Currently, Planet Innovation serves as the contract manufacturer for Quantum-Si’s Platinum® Pro instrument, set to debut in the first half of 2025. Through ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch